IQVIA Holdings Inc. (IQV)
Stock Price Chart
Key Info
| Market Cap | 30.63B |
| Revenue (ttm) | 10.94B |
| Net Income (ttm) | 132.00M |
| Shares Out | 191.27M |
| EPS (ttm) | 0.67 |
| PE Ratio | 238.99 |
| Forward PE | 26.04 |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 11, 2020 |
| Last Price | $160.13 |
| Previous Close | $159.64 |
| Change ($) | 0.49 |
| Change (%) | 0.30% |
| Day's Open | 160.41 |
| Day's Range | 158.94 - 161.96 |
| Day's Volume | 474,632 |
| 52-Week Range | 81.79 - 169.14 |
More Stats
| Market Cap | 30.63B |
| Enterprise Value | 41.95B |
| Earnings Date (est) | Oct 28, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 191.27M |
| Float | 189.78M |
| EPS (basic) | 0.69 |
| EPS (diluted) | 0.67 |
| FCF / Share | 5.13 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 0.42% |
| FCF Yield | 3.20% |
| Payout Ratio | n/a |
| Shares Short | 2.49M |
| Short Ratio | 2.07 |
| Short % of Float | 1.46% |
| Beta | 1.33 |
| PE Ratio | 238.99 |
| Forward PE | 26.04 |
| P/FCF Ratio | 31.28 |
| PS Ratio | 2.80 |
| PB Ratio | 5.51 |
| Revenue | 10.94B |
| Operating Income | 625.00M |
| Net Income | 132.00M |
| Free Cash Flow | 979.00M |
| Net Cash | -11.33B |
| Net Cash / Share | -59.22 |
| Gross Margin | 34.63% |
| Operating Margin | 5.71% |
| Profit Margin | 1.20% |
| FCF Margin | 8.95% |
| ROA | 1.97% |
| ROE | 2.52% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11,088 | 10,412 | 9,702 | 6,815 | 5,737 | 5,460 | 5,100 | 4,866 | 4,328 | 3,924 |
| Revenue Growth | 6.49% | 7.32% | 42.36% | 18.79% | 5.07% | 7.07% | 4.81% | 12.43% | 10.29% | - |
| Gross Profit | 3,788 | 3,666 | 3,401 | 2,067 | 1,621 | 1,501 | 1,337 | 1,233 | 1,142 | 1,119 |
| Operating Income | 777 | 741 | 665 | 576 | 646 | 590 | 462 | 396 | 345 | 395 |
| Net Income | 191 | 259 | 1,277 | 72.00 | 387 | 357 | 227 | 178 | 242 | 161 |
| Shares Outstanding | 195 | 204 | 218 | 149 | 123 | 128 | 124 | 116 | 116 | 116 |
| Earnings Per Share | 0.96 | 1.24 | 5.74 | 0.47 | 3.08 | 2.72 | 1.77 | 1.51 | 2.05 | 1.36 |
| EPS Growth | -22.58% | -78.4% | 1121.28% | -84.74% | 13.24% | 53.67% | 17.22% | -26.34% | 50.74% | - |
| Operating Cash Flow | 1,417 | 1,254 | 970 | 860 | 476 | 433 | 393 | 336 | 161 | 378 |
| Capital Expenditures | -582 | -459 | -369 | -164 | -78.00 | -83.00 | -86.33 | -68.61 | -72.70 | -77.68 |
| Free Cash Flow | 835 | 795 | 601 | 696 | 398 | 350 | 307 | 267 | 88.25 | 300 |
| Cash & Equivalents | 899 | 938 | 1,005 | 1,238 | 977 | 870 | 781 | 571 | 519 | 0.00 |
| Total Debt | 12,041 | 11,007 | 10,225 | 7,200 | 2,468 | 2,283 | 2,046 | 2,422 | 1,972 | - |
| Net Cash / Debt | -11,142 | -10,069 | -9,220 | -5,962 | -1,491 | -1,413 | -1,265 | -1,851 | -1,453 | 0.00 |
| Assets | 23,251 | 22,549 | 22,857 | 21,208 | 3,926 | 3,296 | 3,067 | 2,499 | 2,323 | - |
| Liabilities | 16,988 | 15,595 | 14,613 | 12,348 | 4,262 | 4,000 | 3,734 | 3,858 | 3,293 | - |
| Book Value | 6,003 | 6,714 | 7,995 | 8,633 | -564 | -704 | -667 | -1,360 | -970 | - |
Company Profile
Company Details
| Full Name | IQVIA Holdings Inc. |
| Country | United States |
| Employees | 67,000 |
| CEO | Ari Bousbib |
Stock Information
| Ticker Symbol | IQV |
| Stock Exchange | New York Stock Exchange |
| Unique Identifier | NYSE: IQV |
| IPO Date | May 9, 2013 |
Description
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.